Quantitative assessment of BAX transcript and flow cytometric expression in acute myeloid leukemia: A prospective study

References

• Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993;81:151–7.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322–33.
   PubMed Web of Science ®Google Scholar
• Liu Yin JA, Wheatley K, Rees JK, Burnett AK. Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Brit J Haematol. 2001;113:713–26.
   PubMed Web of Science ®Google Scholar
• Del Poeta G, Venditti A, Del Principe MI, Maurillo L, Buccisano F, Tamburini A, et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003;101:2125–31.
   PubMed Web of Science ®Google Scholar
• Marx D, Binder C, Meden H, Lenthe T, Ziemek T, Hiddemann T, et al. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer. Anticancer Res. 1997;17:2233–40.
   PubMed Web of Science ®Google Scholar
• Friess H, Lu Z, Graber HU, Zimmermann A, Adler G, Korc M, et al. Bax, but not Bcl-2, influences the prognosis of human pancreatic cancer. Gut 1998;43:414–21.
   PubMed Web of Science ®Google Scholar
• Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA. BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol. 1998;16:2583–90.
   PubMed Web of Science ®Google Scholar
• Bairey O, Zimra Y, Shaklai M, Okon E, Rabizadeh E. Bcl-2, Bcl-X, Bax, and Bak expression in short- and long-lived patients with diffuse large B-cell lymphomas. Clin Cancer Res. 1999;5:2860–6.
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Sivridis E, Stathopoulos GP, Fountzilas G, Kalofonos HP, Tsamandas A, et al. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse. Anticancer Res. 2001;21:253–9.
   PubMed Web of Science ®Google Scholar
• Kymionis GD, Dimitrakakis CE, Konstadoulakis MM, Arzimanoglou I, Leandros E, Chalkiadakis G, et al. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients? J Surg Res. 2001;99:161–8.
   PubMed Web of Science ®Google Scholar
• Gessner C, Liebers U, Kuhn H, Stiehl P, Witt C, Schauer J, et al. BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer. Eur Respir J. 2002;19:134–40.
   PubMed Web of Science ®Google Scholar
• Katkoori VR, Suarez-Cuervo C, Shanmugam C, Jhala NC, Callens T, Messiaen L, et al. Bax expression is a candidate prognostic and predictive marker of colorectal cancer. J Gastrointest Oncol. 2010;1:76–89.
   PubMedGoogle Scholar
• Hogarth LA, Hall AG. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood 1999;93:2671–8.
   PubMed Web of Science ®Google Scholar
• Nuessler V, Stötzer O, Gullis E, Pelka-Fleischer R, Pogrebniak A, Gieseler F, et al. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines. Leukemia 1999;13:1864–72.
   PubMed Web of Science ®Google Scholar
• Wuchter C, Karawajew L, Ruppert V, Buchner T, Schoch C, Haferlach T, et al. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia 1999;13:1943–53.
   PubMed Web of Science ®Google Scholar
• Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J, et al. BAX and PKCα modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res. 2000;6:1401–9.
   PubMed Web of Science ®Google Scholar
• Ong YL, McMullin MF, Bailie KE, Lappin TR, Jones FG, Irvine AE. High bax expression is a good prognostic indicator in acute myeloid leukaemia. Brit J Haematol. 2000;111:182–9.
   PubMed Web of Science ®Google Scholar
• Köhler T, Schill C, Deininger MW, Krahl R, Borchert S, Hasenclever D, et al. High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML). Leukemia 2002;16:22–9.
   PubMed Web of Science ®Google Scholar
• Narayan S, Chandra J, Sharma M, Naithani R, Sharma S. Expression of apoptosis regulators Bcl-2 and Bax in childhood acute lymphoblastic leukemia. Hematology 2007;12:39–43.
   PubMed Web of Science ®Google Scholar
• Hess CJ, Berkhof J, Denkers F, Ossenkoppele GJ, Schouten JP, Oudejans JJ, et al. Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia. J Clin Oncol. 2007;25:1209–15.
   PubMed Web of Science ®Google Scholar
• Chleq-Deschamps CM, LeBrun DP, Huie P, Besnier DP, Warnke RA, Sibley RK, et al. Topographical dissociation of BCL-2 messenger RNA and protein expression in human lymphoid tissues. Blood 1993;81:293–8.
   PubMed Web of Science ®Google Scholar
• Kondo E, Nakamura S, Onoue H, Matsuo Y, Yoshino T, Aoki H, et al. Detection of bcl-2 protein and bcl-2 messenger RNA in normal and neoplastic lymphoid tissues by immunohistochemistry and in situ hybridization. Blood 1992;80:2044–51.
   PubMed Web of Science ®Google Scholar
• Akagi T, Kondo E, Yoshino T. Expression of Bcl-2 protein and Bcl-2 mRNA in normal and neoplastic lymphoid tissues. Leuk Lymphoma 1994;13:81–7.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Shinde SC, Kumaran GS, Sapre RS, Dhond SR, Badrinath Y, et al. Haematologic and immunophenotypic profile of acute myeloid leukemia: an experience of Tata Memorial Hospital. Indian J Cancer 2003;40:71–6.
   PubMedGoogle Scholar